Moderna scores FDA authorization for its COVID-19 vaccine, adding key 2nd shot as nationwide campaign ramps up Congressional leaders include surprise billing fix, more provider relief money in COVID-19 package IBM links with Salesforce to offer digital COVID-19 vaccine passports Beckman Coulter plans $4, high-volume COVID-19 antigen test Codagenix, Serum Institute take nasal COVID-19 vaccine into clinic WuXi lays out €150M to take over Bayer plant in Germany, boosting pandemic supply network COVID-19 tracker: Codagenix, Serum Institute launch intranasal vaccine study; Salesforce taps IBM's health pass to help businesses reopen Featured Story | By Eric Sagonowsky When COVID-19 began spreading earlier this year, the prospect of coronavirus vaccines launching before year’s end seemed like the longest of long shots. Now, partly in thanks to the research partnership between the federal government and industry, the U.S. has its second authorized COVID-19 vaccine. scores FDA nod for its COVID shot, adding key 2nd option read more |
| |
|---|
|
Top Stories By Robert King Congressional leaders made an agreement for a new $900 billion COVID-19 relief package that includes a provider-friendly end to surprise medical bills. read more By Conor Hale In the final act of the 2011 film "Contagion," people wore bar-coded wristbands to prove they had been inoculated against the deadly, pandemic virus. But in 2021, of course, the vaccinated will be able to use a blockchain-powered smartphone app, according to IBM and Salesforce. read more By Conor Hale Beckman Coulter plans to launch a $4 coronavirus antigen test designed for mass screening, with the goal of shipping up to 25 million per month by March. read more By Nick Paul Taylor Codagenix and the Serum Institute of India have begun a first-in-human clinical trial of their single-dose intranasal COVID-19 vaccine. The partners are assessing the live attenuated candidate, COVI-VAC, in a 48-subject phase 1 clinical trial in the U.K. read more By Fraiser Kansteiner Shanghai's WuXi Biologics is stumping up €150 million ($183.3 million) to take over Bayer's drug substance manufacturing facility in Wuppertal, Germany. Pending regulatory approval, the deal is expected to close in 2021's first half, with the site expected to kick off drug substance and product manufacturing sometime next year, the companies said. read more By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner Codagenix and the Serum Institute of India started a human study of their single-dose intranasal vaccine hopeful. IBM will use its Digital Health Pass to help Salesforce ease business reopenings. Beckman Coulter is plotting the launch of a $4 antigen test. Plus, Walgreens and CVS kicked off vaccination efforts in long-term care facilities. read more |
